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OBJECTIVE—The physiology of counterregulatory responses
during hypoglycemia in intensively treated type 2 diabetic sub-
jects is largely unknown. Therefore, the speciﬁc aims of the study
tested the hypothesis that 1) 6 months of intensive therapy to
lower A1C 7.0% would blunt autonomic nervous system (ANS)
responses to hypoglycemia, and 2) antecedent hypoglycemia will
result in counterregulatory failure during subsequent hypogly-
cemia in patients with suboptimal and good glycemic control.
RESEARCH DESIGN AND METHODS—Fifteen type 2 diabetic
patients (8 men/7 women) underwent 6-month combination therapy
of metformin, glipizide XL, and acarbose to lower A1C to 6.7% and
2-day repeated hypoglycemic clamp studies before and after inten-
sive therapy. A control group of eight nondiabetic subjects partici-
pated in a single 2-day repeated hypoglycemic clamp study.
RESULTS—Six-month therapy reduced A1C from 10.2  0.5 to
6.7  0.3%. Rates of hypoglycemia increased to 3.2 episodes per
patient/month by study end. Hypoglycemia (3.3  0.1 mmol/l)
and insulinemia (1,722  198 pmol/l) were similar during all
clamp studies. Intensive therapy reduced (P  0.05) ANS and
metabolic counterregulatory responses during hypoglycemia.
Antecedent hypoglycemia produced widespread blunting (P 
0.05) of neuroendocrine, ANS, and metabolic counterregulatory
responses during subsequent hypoglycemia before and after
intensive therapy in type 2 diabetic patients and in nondiabetic
control subjects.
CONCLUSIONS—Intensive oral combination therapy and ante-
cedent hypoglycemia both blunt physiological defenses against
subsequent hypoglycemia in type 2 diabetes. Prior hypoglycemia
of only 3.3  0.1 mmol/l can result in counterregulatory failure in
type 2 diabetic patients with suboptimal control and can further
impair physiological defenses against hypoglycemia in inten-
sively treated type 2 diabetes. Diabetes 58:701–709, 2009
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arge randomized controlled multicenter clinical
trials have demonstrated the beneﬁt of improved
glycemic control on microvascular complications
in both type 1 and type 2 diabetes (1,2). These
compelling data have produced a paradigm shift in the
treatment of diabetes (particularly type 2 diabetes) striv-
ing for A1C values 7.0% (3). The major drawbacks of
tight metabolic control in patients with type 1 diabetes are
well documented and include increased hypoglycemia and
weight gain (4–8).
Recently, three large studies have investigated the ef-
fects of rigorous metabolic control (A1C 7.0%) on the
prevalence of macrovascular disease in type 2 diabetes
(9–11). The overall conclusion of these studies was that
A1C values 7.0% did not produce a statistically signiﬁ-
cant reduction in macrovascular events but did produce a
marked increase in hypoglycemia in type 2 diabetes. The
effects of intensive therapy on physiological counterregu-
latory responses during hypoglycemia in type 2 diabetes
have not been thoroughly investigated. Burge et al. (12)
demonstrated that improving glycemic control during an
8-day in-patient admission could lower symptom re-
sponses and plasma glucose levels for activation of epi-
nephrine during hypoglycemia. Levy et al. (13), using a
cross-sectional study design, also concluded that im-
proved glycemic control in type 2 diabetes shifts the
thresholds for counterregulatory hormone release to
lower plasma glucose concentrations during hypoglyce-
mia. Korzon-Burakowska et al. (14) improved A1C from
11.3  1.1 to 8.1  0.9% during a 4-month period. Thresh-
olds (i.e., plasma glucose values) for counterregulatory
hormone release and epinephrine and cortisol responses
were lowered by improved glycemic control. Spyer et al.
(15), investigating a group of seven type 2 diabetic patients
with an A1C of 7.4%, also found that the glycemic thresh-
olds for counterregulatory hormone release were reduced
from elevated to normal physiological glucose levels.
However, similar to some (13,16) but not all studies (17),
there was no difference in values of the key counterregu-
latory hormones, epinephrine and glucagon, during hypo-
glycemia when compared with nondiabetic control
subjects. Studies investigating the mechanisms regulating
counterregulatory responses during hypoglycemia in type
2 diabetes are even fewer. Segel et al. (16) determined that
antecedent hypoglycemia in a group of type 2 diabetic
patients with an A1C of 8.1% resulted in hypoglycemia-
associated autonomic failure similar to patients with type
1 diabetes. Despite the above data, two questions remain
unanswered: 1) What are the effects of a period of rigorous
glycemic control to reduce A1C 7.0% on counterregula-
tory responses in type 2 diabetes, and 2) what are the
effects of antecedent hypoglycemia on autonomic nervous
system (ANS), neuroendocrine, and metabolic counter-
regulatory mechanisms before and after a period of
rigorous metabolic control in type 2 diabetes? In the
present study, we tested the hypothesis that 6-month
intensive therapy to lower A1C 7.0% would impair
counterregulatory response to hypoglycemia and that an-
tecedent hypoglycemia would further impair key homeo-
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hypoglycemia in type 2 diabetes.
RESEARCH DESIGN AND METHODS
Fifteen patients (8 men/7 women) with type 2 diabetes (age 47  2 years), BMI
of 33  2 kg/m
2, glycosylated hemoglobin of 10.2  0.5% (normal range
4–6.5%), anti-GAD and anti–islet cell antibody negative, and disease duration
of 6  2 years were studied. Patients were receiving diet and exercise (n  2)
or oral agent monotherapy [metformin (mean 750 mg/day, n  10) or
sulfonylurea (glyburide or glipizide mean 5 mg/day, n  3)]. Eight nondiabetic
control subjects (4 men/4 women), aged 48  3 years, BMI 30  2 kg/m
2, and
A1C 5.1  0.2% were also studied. Each subject had a normal blood count,
plasma electrolytes, and liver and renal function. All gave written informed
consent. Studies were approved by the Vanderbilt University Human Subjects
Institutional Review Board.
Type 2 diabetic subjects. Fifteen patients participated in two 2-day hypo-
glycemia experiments separated by 6 months. Subjects were asked to avoid
any exercise and consume their usual weight-maintaining diet for 3 days
before each study. Two days before a study, sulfonylurea and metformin
tablets were omitted. After 6 months when the patients were in good
metabolic control, these medications were replaced with injections of regular
insulin before each meal. The dose of regular insulin was carefully adjusted so
that hypoglycemia (3.9 mmol/l) and hyperglycemia (11.1 mmol/l) were
avoided in the 2 days before a study. Each subject was admitted to the
Vanderbilt General Clinical Research Center (GCRC) at 5:00 P.M.o nt h e
evening before an experiment. At this time, two intravenous cannulae were
inserted under 1% lidocaine local anesthesia. One cannula was placed in a
retrograde fashion into a vein on the back of the hand. This hand would be
placed in a heated box (55–60°C) during the study so that arterialized blood
could be obtained (18). The other cannula was placed in the contralateral arm
for infusions. Patients then received a standardized evening meal, and a
continuous low-dose infusion of insulin was started to normalize plasma
glucose. The insulin infusion was adjusted overnight to maintain blood
glucose between 4.4 and 7.2 mmol/l.
Hypoglycemia experiments. After an overnight 10-h fast at 0 min, a primed
(18 Ci) continuous infusion (0.18 Ci/min) of high-performance liquid
chromatography (HPLC)-puriﬁed [3-
3H]glucose (11.5 mCi  mmol
1  l
1;
Perkin Elmer Life Sciences, Boston, MA) was administered via a precalibrated
infusion pump (Harvard Apparatus, South Natick, MA). A period of 90 min was
allowed to elapse followed by a 30-min basal control period. Plasma glucose
was maintained at euglycemia during this period by continuing the overnight
basal insulin. At time 120 min, a primed constant (15.0 pmol  kg
1  min
1)
infusion of insulin (Human Regular Insulin; Eli Lilly, Indianapolis, IN) was
started and continued until 240 min. The rate of fall of glucose was controlled
(0.07 mmol/min), and the hypoglycemic nadir (3.3 mmol/l) was achieved using
a modiﬁcation of the glucose clamp technique (19). During the clamp period,
plasma glucose was measured every 5 min, and a 20% dextrose infusion was
adjusted so that plasma glucose levels were held constant at 3.3  0.1 mmol/l
(20). Potassium chloride (20 mmol/l) was infused during the clamp to reduce
insulin-induced hypokalemia. After completion of the 2-h test period, the
insulin infusion was turned down to the basal rate, and the plasma glucose
was rapidly restored to euglycemia with 20% dextrose. In the afternoon after
a 2-h period of euglycemia, a second 2-h hypoglycemic clamp of 3.3 mmol/l
was performed similar to the morning study. No tritiated glucose was infused
during the afternoon studies. After completion of the afternoon hypoglycemic
clamp, a basal insulin infusion was restarted and a standardized evening meal
and snack was given. Similar to the previous night, a variable low-dose
infusion was used to maintain glucose levels (4.4–7.2 mmol/l) overnight. The
next morning after a 10-h overnight fast, an identical (including a tritiated
glucose infusion) 2-h hypoglycemic clamp at 3.3  0.1 mmol/l was performed
as described for day 1.
Study medication. After completion of the ﬁrst 2-day clamp studies, patients
were started on triple oral combination therapy. Metformin and acarbose were
increased to 1 g twice a day and 50 mg three times a day over a 4-week period,
respectively. Glipizide XL was increased to 10 mg once or twice a day over a
period of 3 weeks. All patients performed intensive self-reported blood
glucose monitoring before main meals, snacks, and at bedtime or any time
that they felt low glucose or a second individual thought they had a low
glucose. Thus, study subjects tested their glucose levels between four to seven
times per day. Patients were contacted by study nurses twice a week and by
a dietitian weekly to adjust diet, exercise, and medication and to discuss any
treatment side effects. Patients were seen by S.N.D., study nurses, and/or a
dietitian monthly. Patient adherence to protocol was assessed at monthly
visits and found to be excellent. One patient moved out of state during the
6-month treatment period and was lost to follow-up. After completion of the
6-month intensive treatment period, patients were readmitted to the Vander-
bilt GCRC for an identical 2-day hypoglycemic clamp protocol as described
above. The nondiabetic control subjects underwent a single 2-day in-patient
hypoglycemic clamp protocol similar (without overnight glucose control) to
the type 2 diabetic patients.
Direct measurement of muscle sympathetic nerve activity. Muscle
sympathetic nerve activity (MSNA) was recorded from the peroneal nerve at
the level of the ﬁbular head and popliteal fossa (21,22). The approximate
location of this nerve was determined by transdermal electrical stimulation
(10–60 V, 0.01-ms duration). This stimulation produced painless muscle
contraction of the foot. After this, a reference stainless steel microelectrode
with a shaft diameter of 200 m was placed subcutaneously. A similar
tungsten electrode, with an uninsulated tip (1–5 m) was inserted into the
nerve and used for recording of MSNA.
Criteria for acceptable MSNA recordings were 1) electrical stimulation
produced muscle twitches but not paresthesia, 2) nerve activity increased
during phase II of the Valsalva maneuver (hypotensive phase) and was
suppressed during phase IV (blood pressure overshoot), and 3) nerve activity
increased in response to held expiration.
Tracer calculations. Rates of glucose appearance (Ra), endogenous glucose
production (EGP), and glucose utilization were calculated according to the
methods of Wall et al. (23). EGP was calculated by determining the total Ra
(this comprises both EGP and any exogenous glucose infused to maintain the
desired hypoglycemia) and subtracting it from the amount of exogenous
glucose infused. It is now recognized that this approach is not fully quantita-
tive, because underestimates of total Ra and rate of glucose disposal (Rd) can
be obtained. The use of a highly puriﬁed tracer and taking measurements
under steady-state conditions (i.e., constant speciﬁc activity) in the presence
of low glucose ﬂux eliminates most, if not all, of the problems. In addition, to
maintain a constant speciﬁc activity, isotope delivery was increased commen-
surate with increases in exogenous glucose infusion. During these studies,
only glucose ﬂux results from the steady-state basal and the ﬁnal 30-min
periods of the hypoglycemic clamps are reported.
Analytical methods. Plasma glucose concentrations were measured in
triplicate using the glucose oxidase method with a glucose analyzer (Beck-
man, Fullerton, CA). Glucagon was measured according to a modiﬁcation of
the method of Aguilar-Parada et al. (24) with an interassay coefﬁcient of
variation (CV) of 12%. Insulin was measured as previously described (25) with
an interassay CV of 9%. Catecholamines were determined by HPLC (26) with
an interassay CV of 12% for epinephrine and 8% for norepinephrine. Two
modiﬁcations to the procedure for catecholamine determination were made:
1) a ﬁve-point rather than a one-point standard calibration curve was used,
and 2) the initial and ﬁnal samples of plasma with known amounts of
epinephrine and norepinephrine were spiked so that accurate identiﬁcation of
the relevant respective catecholamine peaks could be made. Cortisol was
assayed using the Clinical Assays Gamma Coat Radioimmunoassay (RIA) kit
with an interassay CV of 6%. Growth hormone was determined by RIA (27)
with a CV of 8.6%. Pancreatic polypeptide was measured by RIA using the
method of Hagopian et al. (28) with an interassay CV of 8%. Lactate, glycerol,
alanine, and -hydroxybutyrate were measured in deproteinized whole blood
using the method of Lloyd et al. (29). Nonesteriﬁed fatty acids (NEFAs) were
measured using the WAKO kit adopted for use on a centrifugal analyzer (30).
Blood for hormones and intermediary metabolites were drawn twice
during the control period and every 15 min during the experimental period.
Cardiovascular parameters (pulse, systolic, diastolic, and mean arterial pres-
sure) were measured noninvasively by a Dinamap (Critikon, Tampa, FL) every
10 min throughout each study starting at 80 min.
Hypoglycemic symptoms were quantiﬁed using a previously validated
semiquantitative questionnaire (31). Each individual was asked to rate his or
her experience of the symptoms twice during the control period and every 15
min during experimental periods. Symptoms measured included sweaty,
tremor/shaky, hot, thirsty/dry mouth, agitation/irritability, palpitations, tired/
fatigued, confusion, dizzy, difﬁculty thinking, blurriness of vision, and sleepy.
The ratings of the ﬁrst six symptoms were summed to get the autonomic
score, whereas the ratings from the last six symptoms provide a neuroglyco-
penic symptom score.
Statistical analysis. Data are expressed as mean  SE and were analyzed
using standard, parametric, one- and two-way ANOVA, and repeated measures
where appropriate (SigmaStat; SPSS Science, Chicago). Tukey’s post hoc
analysis was used to delineate statistical signiﬁcance across time within each
group and for each group compared with day 1 of the preintensive therapy
group. A P value of 0.05 was accepted as statistically signiﬁcant. The
baseline and ﬁnal 30 min of hypoglycemia were compared for most parame-
ters, because steady-state glucose levels, insulin levels, and glucose infusion
rates were achieved by this time.
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Effects of 6-month intensive therapy on counterregu-
latory responses to hypoglycemia, insulin, glucose,
and A1C levels. A1C levels were reduced from 10.2  0.5
to 6.7  0.3% during the 6 months of intensive therapy.
Body weight remained stable throughout 6 months of
intensive therapy (97.6  7 to 96.1  6 kg). Plasma glucose
levels were controlled overnight and were similar at the
start of the preintensive therapy and postintensive therapy
(5.6  0.3 and 5.3  0.2 mmol/l, respectively). Basal
plasma glucose levels in the control group were also
equivalent at 5.3  0.2 mmol/l. Plasma glucose levels
(3.3  0.1 mmol/l) were equivalent during preintensive
therapy, postintensive therapy, and control hypoglycemic
clamps (Fig. 1).
Basal insulin levels were 198  36, 210  30, and 66 
18 pmol/l in the preintensive therapy, postintensive ther-
apy, and control groups, respectively. Insulin levels during
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FIG. 2. Plasma epinephrine, glucagon, and cortisol levels in the ﬁnal 30 min of hypoglycemia during repeated 2-day hyperinsulinemic-hypoglycemic
clamps in overnight-fasted individuals with type 2 diabetes and healthy control subjects. *Plasma epinephrine, glucagon, and cortisol levels are
signiﬁcantly reduced (P < 0.05) after day 1 hypoglycemia in healthy control subjects and patients with type 2 diabetes both before (pre) and after
(post) 6-month intensive triple oral combination anti-diabetes therapy. †Plasma epinephrine levels are signiﬁcantly reduced (P < 0.05) after
6-month intensive triple oral combination anti-diabetes therapy. ‡Plasma cortisol levels are signiﬁcantly reduced (P < 0.05) in healthy control
subjects compared with type 2 diabetic patients before intensive therapy.
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FIG. 1. Plasma glucose and insulin levels during repeated 2-day hyperinsulinemic-hypoglycemic clamps in overnight-fasted individuals with type
2 diabetes and healthy control subjects. Type 2 diabetic patients are studied before (pre) and after (post) 6 months of intensive triple oral
combination anti-diabetes therapy. F, Day 1 pre; f, day 2 pre; Œ, day 1 post; ƒ, day 2 post; , day 1 controls; E, day 2 controls.
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pmol/l). C-peptide levels decreased from 0.75  0.12 to
0.17  0.02 ng/l during hypoglycemia in preintensive
therapy. After intensive therapy, basal C-peptide levels
were increased (1.2  0.2 ng/ml; P  0.05) and were higher
during postintensive therapy clamps (0.3  0.03 ng/l; P 
0.05) compared with preintensive therapy.
Neuroendocrine responses. After 6-month intensive
therapy, epinephrine responses were signiﬁcantly blunted
in postintensive therapy compared with preintensive ther-
apy and control values (2,033  343 vs. 3,788  414 and
3,837  441 pmol/l, respectively; P  0.05) (Fig. 2).
Intensive therapy had no effect on other neuroendocrine
(glucagon, growth hormone, cortisol, norepinephrine, or
pancreatic polypeptide) responses to hypoglycemia (Fig.
3). Cortisol levels were higher (P  0.05) in preintensive
therapy compared with control subjects (801  77 vs.
635  80 nmol/l).
Glucose kinetics and intermediary metabolism.
Basal EGP was similar in all three groups (preintensive
therapy, 9.9  1.1; postintensive therapy, 9.5  1.1; control,
9.4  1.1 mol  kg
1  min
1). EGP declined signiﬁcantly in
all three groups (P  0.01). However, EGP was higher (P 
0.01) during hypoglycemia in preintensive therapy (6.6 
1.1 mol  kg
1  min
1) compared with postintensive
therapy and control values where there was no measur-
able EGP. Rates of glucose infusion were signiﬁcantly
greater (P  0.01) in postintensive therapy (10.5  3.3
mol  kg
1  min
1) and control (16.5  3.9 mol  kg
1 
min
1) compared with preintensive therapy (2.2 mol 
kg
1  min
1).
Intermediary metabolism. NEFAs (193  22 vs. 303 
38 mol/l), lactate (1.52  0.17 vs. 1.96  0.18 mmol/l), and
glycerol (49  7 vs. 69  9 mol/l) were signiﬁcantly
blunted (P  0.05) during postintensive therapy compared
with preintensive therapy, respectively (Fig. 4). Plasma
lactate, glycerol, and blood NEFA levels were higher (P 
0.05) during preintensive therapy versus control.
MSNA. Basal rates of MSNA were similar in preintensive
therapy (34  3 bursts/min), postintensive therapy (31  4
bursts/min), and control (38  6 bursts/min). MSNA in-
creased by 17  3 bursts/min during preintensive therapy,
which was increased (P  0.05) compared with the
responses during postintensive therapy (5  3 bursts/min)
and control clamps (8  2 bursts/min) (Fig. 5).
Hypoglycemic symptom scores. Total hypoglycemic
scores increased by 33  6 during hypoglycemia in prein-
tensive therapy, which was increased (P  0.01) compared
with the response during postintensive therapy (19  4).
Symptom responses were lower (P  0.01) in control
(12  2) compared with both preintensive therapy and
postintensive therapy studies (Fig. 5). Intensive treatment
blunted autonomic symptom responses (preintensive ther-
apy, 18  3, vs. postintensive therapy, 10  4; P  0.05)
and neuroglycopenic symptom responses to hypoglycemia
(15  3 vs. 9  3; P  0.05).
Cardiovascular responses. Intensive therapy signiﬁ-
cantly blunted cardiovascular responses to hypoglycemia.
Systolic blood pressure increased from 120  6t o1 2 9 6
mmHg (P  0.05) during hypoglycemia in preintensive
therapy but remained similar to baseline (129  6t o1 3 0
7 mmHg) in postintensive therapy. Heart rate also in-
creased during hypoglycemia in preintensive therapy
(74  5t o8 5 6 beats/min; P  0.05) but remained similar
to baseline (70  4t o7 3 4 beats/min) in postintensive
therapy. Systolic blood pressure increased by a nonsignif-
icant amount in control subjects (119  5t o1 2 5 4
mmHg), but heart rate increased signiﬁcantly (62  4t o
72  4 beats/min; P  0.05).
Hypoglycemic events during intensive treatment.
Self-reported blood glucose readings 3.9 mmol/l are
shown in Table 1. No patient experienced any hypoglyce-
mia in the month before the start of the study. During the
study, all patients experienced hypoglycemic readings
between 3.3 and 3.9 mmol/l. Thirteen patients had readings
between 2.8 and 3.3 mmol/l, and frequency of hypoglyce-
mia increased to 3.2 episodes per patient per month by the
end of the 6-month study. No major episodes of hypogly-
cemia occurred during the study. Four patients docu-
mented hypoglycemic readings 2.8 mmol/l.
Effects of antecedent hypoglycemia on counterregu-
latory responses to hypoglycemia before and after
6-month intensive therapy
Insulin, C-peptide, and glucose levels. Insulin levels
were similar during the morning of day 1 and day 2 clamp
studies in all three groups (1,534  174 to 1,890  222
pmol/l). Plasma glucose levels were equivalent during
morning day 1 and day 2 studies (3.3  0.1 mmol/l) in all
groups. Antecedent hypoglycemia attenuated the fall in
C-peptide during day 2 in both preintensive therapy (day 1,
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FIG. 3. Plasma growth hormone and pancreatic polypeptide levels in the ﬁnal 30 min of hypoglycemia during repeated 2-day hyperinsulinemic-
hypoglycemic clamps in overnight-fasted individuals with type 2 diabetes and healthy control subjects. *Plasma growth hormone and pancreatic
polypeptide levels are signiﬁcantly reduced (P < 0.05) after day 1 hypoglycemia in healthy control subjects.
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sive therapy studies (day 1, 0.98  0.15, vs. day 2,
0.61  0.11 ng/l; P  0.05).
Neuroendocrine levels. Baseline neuroendocrine hor-
mone levels were similar at the start of preintensive
therapy, postintensive therapy, and control studies (Table
Day 1-Pre
Day 2-Pre
Day 1-Post
Day2 - Post
Day 1-Controls
Day 2-Controls
0
20
40
60
80
100
*
* *
 † ‡
B
l
o
o
d
 
G
l
y
c
e
r
o
l
 
(
µ
m
o
l
/
L
)
Day 1-Pre
Day 2-Pre
Day1 - Post
Day2 - Post
Day 1-Controls
Day 2-Controls
0.0
0.5
1.0
1.5
2.0
2.5
** *
 † ‡
B
l
o
o
d
 
L
a
c
t
a
t
e
 
(
m
m
o
l
/
L
)
Day 1-Pre
Day 2-Pre
Day1 - Post
Day2 - Post
Day 1-Controls
Day 2-Controls
0
100
200
300
400
*  †
‡
N
E
F
A
 
(
µ
m
o
l
/
L
)
FIG. 4. Blood glycerol, lactate, and plasma NEFA levels in the ﬁnal 30 min of hypoglycemia during repeated 2-day hyperinsulinemic-hypoglycemic
clamps in overnight-fasted individuals with type 2 diabetes and healthy control subjects. *Blood glycerol, lactate, and plasma NEFA levels are
signiﬁcantly reduced (P < 0.05) in healthy control subjects and patients with type 2 diabetes both before (pre) and after (post) 6-month intensive
triple oral combination anti-diabetes therapy. †Blood glycerol, lactate, and plasma NEFA levels are reduced (P < 0.05) after 6-month intensive
therapy in type 2 diabetes. ‡Blood glycerol, lactate, and plasma NEFAs are signiﬁcantly reduced (P < 0.05) in healthy control subjects compared
with type 2 diabetes before intensive therapy.
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FIG. 5.  responses from baseline in MSNA and hypoglycemic symptom scores in the ﬁnal 30 min of hypoglycemia during repeated 2-day
hyperinsulinemic-hypoglycemic clamps in overnight-fasted individuals with type 2 diabetes and healthy control subjects. * MSNA and symptom
responses are signiﬁcantly reduced (P < 0.05) in type 2 diabetic patients and healthy control subjects. † MSNA and symptom responses are
signiﬁcantly reduced (P < 0.05) in type 2 diabetes after 6-month intensive triple oral combination anti-diabetic therapy. ‡ MSNA and symptom
responses are signiﬁcantly reduced (P < 0.05) in healthy control subjects compared with type 2 diabetes before intensive therapy (PRE).
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ent hypoglycemia signiﬁcantly blunted day 2 epinephrine
levels in preintensive therapy (day 1, 3,788  414, vs. day
2, 2,191  332 pmol/l; P  0.01), postintensive therapy (day
1, 2,033  343, vs. day 2, 1,281  316 pmol/l; P  0.05), and
control groups (day 1, 3,837  441, vs. day 2, 1,880  611
pmol/l; P  0.05). Plasma glucagon levels were also
signiﬁcantly blunted by antecedent hypoglycemia in pre-
intensive therapy (day 1, 81  7, vs. day 2, 49  5 ng/l; P 
0.05), postintensive therapy (day 1, 74  11, vs. day 2, 50 
5.2 ng/l; P  0.05), and control groups (day 1, 83  12, vs.
63  7 ng/l; P  0.05). Similarly, cortisol levels were
blunted by antecedent hypoglycemia in preintensive ther-
apy (day 1, 801  77 vs. 635  75 nmol/l; P  0.05),
postintensive therapy (day 1, 718  72, vs. day 2, 582  88
nmol/l; P  0.05), and control groups (day 1, 635  80, vs.
day 2, 492  86 nmol/l; P  0.05). Antecedent hypoglyce-
mia did not signiﬁcantly blunt day 2 growth hormone,
pancreatic polypeptide, or norepinephrine responses in
the preintensive therapy or postintensive therapy patient
studies. However, growth hormone (day 1, 7.8  0.6, vs.
day 2, 3.9  0.4 ng/l; P  0.05) and pancreatic polypeptide
(day 1, 128  26, vs. day 2, 83  28 ng/l; P  0.05) levels
were signiﬁcantly blunted by antecedent hypoglycemia in
the control group.
Glucose kinetics. Glucose speciﬁc activity was in a
steady state at the start and ﬁnal 30 min of each hypogly-
cemic clamp (Table 3). Antecedent hypoglycemia signiﬁ-
cantly reduced EGP during preintensive therapy (day 1,
6.6  0.6, vs. day 2, 0.6  1.1 mol  kg
1  min
1; P  0.01).
EGP was not measurable during both days of postinten-
sive therapy and control studies. Antecedent hypoglyce-
mia resulted in greater glucose infusion rates to maintain
target glucose in preintensive therapy (day 1, 2.2  1.1, vs.
day 2, 8.8  1.6 mol  kg
1  min
1; P  0.05), postintensive
therapy (day 1, 10.5  3.3, vs. day 2, 15.4 
2.7 mol  kg
1  min
1; P  0.05), and control (day 1,
16.5 3.3, vs. day 2, 23.1 3.9 mol kg
1min
1;P0.05).
Intermediary metabolism. Plasma glycerol responses
were blunted (P  0.05) by antecedent hypoglycemia in
preintensive therapy (day 1, 13  3, vs. day 2, 3  1
mol/l), postintensive therapy (day 1, 2  1, vs. day 2,
18  3 mol/l), and control studies (day 1, 22  3, vs.
day 2, 41  4 mol/l). Similarly, plasma lactate levels
were also blunted (P  0.05) by day 1 hypoglycemia in
preintensive therapy (day 1, 1.95  0.2, vs. day 2, 1.31 
0.2 mmol/l), postintensive therapy (day 1, 1.5  0.22, vs.
day 2, 1.2  0.1 mmol/l), and control (day 1, 1.6  0.1, vs.
day 2, 1.4  0.1 mmol/l).
MSNA. Day 1 hypoglycemia reduced MSNA responses
during day 2 hypoglycemia in preintensive therapy (17  3
vs. 4  2 bursts/min; P  0.05) and in control (8  2 vs. 3 
2 bursts/min; P  0.05, respectively). MSNA responses
during day 1 hypoglycemia in postintensive therapy were
signiﬁcantly blunted by intensive treatment and did not
decline further during day 2 hypoglycemia (5  2 vs. 6 
1 bursts/min).
Hypoglycemia symptoms. Day 1 hypoglycemia reduced
symptom responses (P  0.05) during day 2 hypoglycemia
in preintensive therapy 33  6 vs. 16  5) and postinten-
sive therapy (19  4 vs. 10  3). Symptoms were un-
changed during day 1 and day 2 hypoglycemia in control
(12  2 vs. 11  4). Day 1 hypoglycemia blunted (P  0.05)
both autonomic (18  3 vs. 9  4) and neuroglycopenic
(15  4 vs. 7  2) scores during day 2 hypoglycemia in
preintensive therapy. In postintensive therapy, day 1 hy-
poglycemia predominantly blunted day 2 neuroglycopenic
symptoms (7  2 vs. 3  2).
Cardiovascular responses. Blood pressure and heart
rate responses were similar during day 1 and day 2
hypoglycemia in all groups.
DISCUSSION
This study has prospectively determined the effects of
6-month intensive triple combination oral therapy with
improvement of A1C to 6.7% on integrated counterregula-
tory responses during repeated hypoglycemia in a group of
patients with type 2 diabetes. Our results demonstrate that
intensive treatment with oral combination therapy sub-
stantially reduces ANS and metabolic (EGP, lipolysis)
TABLE 1
Self-reported blood glucose readings (3.9 mmol/l) by patients
during 6-month intensive treatment period
Month
Total
readings
3.9
mmol/l 123456
Level of hypoglycemia
3.3–3.9 mmol/l 12 26 27 33 26 34 158
2.9–3.3 mmol/l 5866 1 2 1 3 5 0
2.9 mmol/l 73221 1 5
Total episodes
recorded 17 41 36 41 40 48
Frequency per
patient/month 1.1 2.7 2.4 2.7 2.7 3.2
All 15 patients recorded episodes of hypoglycemia (3.9 mmol/l)
during the 6-month intensive treatment period.
TABLE 2
Baseline neuroendocrine hormone levels at the start of day 1 and day 2 hyperinsulinemic-hypoglycemic clamps in healthy individuals
(control) and patients with type 2 diabetes preintensive therapy and postintensive therapy
Type 2 diabetes Healthy individuals
Preintensive therapy Postintensive therapy Control
Day 1 Day 2 Day 1 Day 2 Day 1 Day 2
Epinephrine (pg/ml) 278  82 180  38 202  44 218  33 223  48 184  48
Norepinephrine (pg/ml) 1.07  0.15 1.0  0.14 0.9  0.2 0.9  0.18 0.7  0.2 1.17  0.26
Glucagon (ng/l) 54  54 5  54 8  34 6  44 8  84 7  6
Growth hormone (g/l) 2  12  0.5 1  0.5 1.5  0.5 1  0.3 1  0.2
Cortisol (pmol/l) 345  61 248  69 248  55 237  44 254  43 235  58
Pancreatic polypeptide (pmol/l) 48  19 31  93 0  92 9  82 8  82 5  7
Data are means  SE.
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Additionally, antecedent hypoglycemia can produce fur-
ther widespread (i.e., neuroendocrine) reductions in the
above physiological counterregulatory mechanisms in
type 2 diabetic patients both before and after intensive
therapy.
Three recent large multicentered trials have examined
the effects of intensive glucose control with an average
A1C 7.0% on macro- and microvascular complications in
type 2 diabetes (9–11). All three studies identiﬁed an
increased prevalence of hypoglycemia with lowering of
A1C in type 2 diabetes (9–11). To date, there are no
published prospective studies examining the effects of
intensive glucose control (i.e., A1C 7.0%) on physiologi-
cal responses to hypoglycemia in type 2 diabetes. Our
study demonstrates that achieving an A1C of 6.7% with
triple oral therapy (glipizide XL, metformin, and acarbose)
for 6 months in the absence of exogenous insulin therapy
can signiﬁcantly reduce neuroendocrine, metabolic, and
ANS responses to hypoglycemia. Furthermore, repeated
episodes of relatively mild hypoglycemia (3.3 mmol/l) can
further signiﬁcantly reduce counterregulatory responses
in type 2 diabetic patients, thus creating a syndrome of
hypoglycemia-associated autonomic failure that occurs
irrespective of moderate or tight glycemic control.
The patients in the present study were diagnosed with
type 2 diabetes for a mean of 6  2 years, which was
similar to Spyer et al. (15) and Israelian et al. (17) but of a
shorter duration than other recent studies investigating
counterregulatory responses to hypoglycemia in type 2
diabetes (12–14,16). Thus, the present results provide data
in a group of more recently diagnosed individuals whom
may be predicted to beneﬁt most from rigorous metabolic
control. Additionally, it should be noted that the results in
this present study are applicable to a group of patients
whom underwent a period of signiﬁcant glycemic control
with a speciﬁc triple oral therapy and lifestyle change
regimen. Thus, we cannot determine whether other ther-
apeutic regimens (i.e., with insulin, thiazolidinediones,
and/or agents that increase GLP-1 axis activity) would
have produced similar results. Intensive therapy in this
study had marked effects on blunting ANS responses to
hypoglycemia. The key counterregulatory hormone epi-
nephrine was reduced by 50%. Similarly MSNA was
reduced by 66%, and hypoglycemic symptom scores
were blunted by 40%. Additionally, blood pressure and
heart rate responses were also signiﬁcantly blunted by
intensive therapy. The above results demonstrate that
central sensing of hypoglycemia combined with end-organ
responses were both reduced by intensive therapy. The
reduced sympathetic nervous system activity also affected
important metabolic counterregulatory mechanisms dur-
ing hypoglycemia after intensive therapy. EGP was not
measurable and lipolysis (NEFA, glycerol) together with
glycogenolysis (lactate) were reduced by 30% after in-
tensive therapy. However, it should be noted that with the
exception of epinephrine (which was lower during postint-
ensive therapy compared with control), intensive therapy
reduced the exaggerated counterregulatory responses ob-
served in the preintensive therapy patients to the usual
physiological responses observed in the control subjects.
Additionally, we would like to point out that the above
metabolic ﬁndings may have been caused by a combina-
tion of reduced ANS input and improvement in glucotox-
icity/insulin sensitivity (32,33). We did not identify any
effects of intensive therapy to signiﬁcantly blunt other
neuroendocrine responses (glucagon, cortisol, growth hor-
mone, norepinephrine, and pancreatic polypeptide). With
the exception of cortisol, levels of the above neuroendo-
crine hormones were not different from age- and BMI-
matched nondiabetic individuals. Spyer et al. (15) also
reported similar ﬁndings in a group of type 2 diabetes with
an A1C of 7.4%. However, Israelian et al. (17) reported that
both glucagon and growth hormone responses were
blunted during similar hypoglycemic conditions to this
study in type 2 diabetic subjects. The fact that the blunting
effects of intensive therapy on counterregulatory re-
sponses in this study were conﬁned almost exclusively to
the sympathetic nervous system is different to the situa-
tion in type 1 diabetes where intensive therapy has been
reported to result in a more widespread blunting of
neuroendocrine responses during hypoglycemia (34). The
reasons for the targeted effects on the sympathetic ner-
vous system are not apparent from the present study.
Previous work (13,14) has determined that the threshold
for counterregulatory hormone release in type 2 diabetes
remain elevated, even during relatively good glycemic
control (A1C 7.4%). Thus, we believe that it is unlikely that
the depth of hypoglycemia in our study (3.3 mmol/l) could
have mitigated against ﬁnding a difference in neuroendo-
crine responses after intensive therapy. In addition, the
magnitude of the neuroendocrine responses was sufﬁ-
ciently robust to have been able to determine a difference
if one had been present. However, we cannot exclude the
possibility that deeper hypoglycemia may have provoked a
more widespread difference in maximal neuroendocrine
responses between the preintensive therapy and post-
intensive therapy treatment groups (13,14).
The second part of our study addressed a possible
mechanism for our ﬁndings of reduced counterregulatory
TABLE 3
Glucose speciﬁc activity (dpm/mmol) during the basal period and the ﬁnal 30 min of day 1 and day 2 hyperinsulinemic-hypoglycemic
clamps in healthy individuals (control) and patients with type 2 diabetes preintensive therapy and postintensive therapy
100 min 110 min 120 min 210 min 225 min 240 min
Preintensive therapy type 2 diabetes
Day 1 286  33 283  31 279  27 310  27 314  26 306  25
Day 2 299  40 300  35 305  36 303  21 295  21 304  22
Postintensive therapy type 2 diabetes
Day 1 257  51 266  51 265  50 290  41 288  43 290  42
Day 2 330  27 329  26 325  26 332  20 336  20 326  20
Control
Day 1 373  30 374  30 374  29 306  26 320  29 312  33
Day 2 370  30 375  36 363  33 308  34 295  39 294  38
Data are means  SE.
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We tested the hypothesis that antecedent hypoglycemia
was a mechanism responsible for acquired counterregula-
tory failure during hypoglycemia in type 2 diabetes. Self-
reported blood glucose monitoring of four to six times per
day had demonstrated an aggregate frequency of hypogly-
cemia of 36–48 episodes per month or up to 3.2 events per
patient a month. More than 95% of these episodes were in
the range of 2.8–3.9 mmol/l. Although this level of hypo-
glycemia is often considered “mild” in clinical practice,
these present results clearly demonstrate the profound
blunting effects of a plasma glucose of 3.3 mmol/l on
subsequent physiological responses to hypoglycemia. Epi-
nephrine and symptom responses were blunted by ante-
cedent hypoglycemia in both preintensive therapy and
postintensive therapy studies. Of note, despite equivalent
insulinemia and glycemia, antecedent hypoglycemia
blunted the fall of C-peptide during day 2 hypoglycemia in
both preintensive therapy and postintensive therapy stud-
ies. This obviously causes some concern because suppres-
sion of endogenous insulin during hypoglycemia is a
primary physiological counterregulatory defense. MSNA
was substantially reduced during day 2 hypoglycemia in
preintensive therapy. However, due to the inherent blunt-
ing effects of intensive therapy, MSNA was substantially
suppressed during day 1 hypoglycemia in postintensive
therapy and was not further reduced during day 2 hypo-
glycemia.
Cortisol and glucagon responses were signiﬁcantly re-
duced by antecedent hypoglycemia in both preintensive
therapy and postintensive therapy studies. In addition to
the above, growth hormone and pancreatic polypeptide (a
marker of parasympathetic activity) were both blunted by
antecedent hypoglycemia in nondiabetic control studies.
Our present ﬁndings extend the elegant studies of Segel et
al. (16) whom also described blunting of ANS and neu-
roendocrine responses after antecedent hypoglycemia in
longer duration, moderately controlled (A1C 8.6  1.1%)
type 2 diabetic patients. The widespread reduction of ANS
and neuroendocrine responses after day 1 hypoglycemia
also led to signiﬁcant blunting of metabolic counterregu-
latory mechanisms (glucose kinetics, lipolysis, and glyco-
genolysis) in both preintensive therapy and postintensive
therapy studies. As discussed, type 2 diabetic patients
typically have higher thresholds (i.e., increased plasma
glucose values) for counterregulatory defenses against
hypoglycemia (7). This is an important protective mecha-
nism that serves to reduce hypoglycemia in type 2 diabe-
tes. The ﬁndings of increased MSNA, cortisol, and
symptom scores coupled with elevated EGP, lipolysis, and
glycogenolysis in preintensive therapy compared with the
nondiabetic control subjects are consistent with higher
plasma glucose thresholds and/or glucotoxicity providing
added protection against hypoglycemia in these individu-
als. Thus, the ﬁnding that antecedent hypoglycemia and
intensive glucose control reduced counterregulatory de-
fenses (e.g., symptoms, EGP, and MSNA) back down to
normal control values indicates that the risk for iatrogenic
hypoglycemia had been increased as important physiolog-
ical protective mechanisms against hypoglycemia had
been removed in these type 2 diabetic patients.
A limitation of this study was that cognitive function
was not formally assessed during our repeat hypoglycemia
studies before and after intensive therapy. We did not
identify any gross changes in cognitive function within our
type 2 diabetic patients or healthy control subjects during
any of our hypoglycemia studies. Whether this indicates
that cognitive function is relatively preserved during re-
peated hypoglycemia and intensive therapy or that more
sophisticated methodology is needed to detect differences
in cognitive function will require further study.
In summary, this present study has demonstrated that
6-month intensive glycemic control with triple oral com-
bination therapy to near-normal A1C levels can result in
substantial reductions of epinephrine responses during
hypoglycemia in individuals with type 2 diabetes. In addi-
tion, the exaggerated neuroendocrine, ANS, and metabolic
counterregulatory responses that were present in the
preintensive therapy group (and thus acting as increased
defenses against hypoglycemia) were reduced to levels
similar to the nondiabetic control group. Near normaliza-
tion of A1C resulted in an increased frequency of 3.0
hypoglycemic episodes per patient month by study end.
Our results clearly demonstrate that antecedent hypogly-
cemia can also induce ANS, neuroendocrine, and meta-
bolic counterregulatory failure in type 2 diabetic patients
with either elevated or near-normal glycemic control.
Furthermore, the combination of repeated hypoglycemia
and intensive glycemic control produces additive effects to
further reduce physiological defenses against subsequent
hypoglycemia. Therefore, we would conclude that ante-
cedent hypoglycemia appears to be the likely cause of the
blunted sympathoadrenal counterregulatory responses oc-
curring during hypoglycemia after intensive treatment in
our type 2 diabetic patients. Additionally, even relatively
mild hypoglycemia (3.3  0.1 mmol/l) can produce signif-
icant blunting of subsequent counterregulatory mecha-
nisms in type 2 diabetes and increase the risk for future
hypoglycemia. This further reinforces the therapeutic goal
of achieving good glycemic control while minimizing the
occurrence of any hypoglycemia.
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